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Abstract: The recent proliferation of probiotics in supermarkets, drugstores and on the 
Internet requires consideration of their unique properties in establishing an appropriate 
framework for their regulation. Although a separate regulatory category at the Food and 
Drug Administration is not justified, certain reforms should be considered to achieve 
more efficient regulation and greater reliability on probiotic product claims. 
Main Text:  
Initial findings of the Human Microbiome Project (HMP), an NIH Common Fund 
initiative, to characterize the microorganisms that live in and on the human body and 
analyze their role in health and disease, were published a little over a year ago (1).   
While the findings raise more questions than they answer about the role and variation 
of microorganisms within individuals and across populations, they have already begun 
to promote the development of probiotics, substances containing live microorganisms 
2 
 
that have a beneficial effect when taken in sufficient quantities (2) and “designed to 
intentionally manipulate microbiome and host properties”(3).  The findings will also 
provide a “baseline” by which to measure changes in an individual’s microbiome 
produced by the consumption of probiotic products. 
Most probiotics currently on the market are sold as foods or dietary supplements. 
Probiotics have been consumed for centuries in the form of yogurts and fermented 
milks. In recent years the variety of probiotic foods on supermarket shelves has 
significantly expanded, and probiotic dietary supplements are being aggressively 
marketed in retail stores and on the Internet.  Although no probiotic has been approved 
for therapeutic purposes, a number are undergoing clinical trials and may soon be 
marketed as biologics or other drugs (4).  There is already a body of published evidence 
of the potential benefit of some strains and species of probiotics for a variety of 
indications (5).   
In addition to promoting the development of novel clinical therapies, the HMP is likely 
to increase the number of probiotic foods and dietary supplements available to 
consumers as well as the claims made about them (6). Consumer demand for these 
products is growing in large part because of their health and wellness claims (7).  Reid et 
al. (8) and others (9) have asserted that while some of these claims may have merit, 
others do not. Many probiotics have not been adequately tested for efficacy yet “make 
claims that lead consumers . . . to believe that they are using reliable products”(8).  
One of the goals of the HMP was to study the ethical, legal and social issues (ELSI) raised 
by human microbiome research. One such issue is whether the current regulatory 
framework for probiotics: 1) adequately addresses issues of safety and effectiveness; 2) 
provides sufficient information to consumers to make informed choices about 
purchasing probiotic products; and 3) sufficiently allows for, or at least does not 
discourage, research on the potential therapeutic benefits of probiotics.  These 
questions were addressed as part of an NIH HMP-funded ELSI study which brought 
together a Working Group (WG) of  human microbiome researchers, legal academics, 
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food and drug law attorneys,  consumer advocates, bioethicists, industry 
representatives, an official from the US Federal Trade Commission (FTC) and a 
representative from Health Canada’s Natural Health Products Directorate (10). 
(Although officials from the US Food and Drug Administration (FDA) were invited to 
participate as members of the WG, they declined to do so because of the perceived 
problem of a conflict of interest arising from a project that might result in 
recommendations to change the FDA’s approach to regulating probiotics (11)). This 
article reports on several of the WG’s observations about the regulatory process for 
probiotics and potential areas for reform.  
To date, FDA’s approach to probiotic products has relied entirely on its existing 
regulatory framework. That is, FDA has no definition of probiotics and regulates them 
based on whether they fall into one of the existing regulated product categories (12), 
i.e., drugs, biologics, foods, food additives, medical foods, foods for special dietary use, 
dietary supplements, medical devices, or cosmetics. (See Table 1.) Because probiotics 
fall into multiple categories, expertise about them is spread unevenly across multiple 
centers at the FDA without a single authoritative agency voice on the issue. This has led 
to inter-center inconsistencies in interpretation and application of regulations, data 
requirements, and the content of potentially relevant guidance documents.  There 
appears to be uncertainty at times about whether a probiotic product should be 
regulated by the Center for Food Safety and Applied Nutrition, the Center for Biologic 
Evaluation and Research or the Center for Drug Evaluation and Research.   
Apart from classification uncertainty, regulatory approaches developed for other 
products may not be a good fit for probiotics or may need to take into account some of 
the unique features of probiotics. By their very nature, probiotics are live organisms that 
are dynamic and unlike chemicals. Probiotics are also likely to lose viability and degrade 
under certain circumstances. Probiotic research and manufacturing involve 
consideration of variables such as the effect of the environment on the viability and 
effectiveness of the probiotics and the interaction between the human body’s biology 
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and biochemistry and the human microbiome, including factors within the human body 
that may activate or deactivate the probiotics. Without stringent manufacturing 
procedures and quality controls, specific probiotics may lose the properties that once 
formed their isolation and selection criteria (13).  Animal models may be of limited 
utility because of the significant differences between human and animal microbiomes 
and immune systems. Finally, many probiotics are consumed by individuals on a daily 
basis as foods making dosing of probiotics for therapeutic purposes challenging.  
An example of the questionable fit between traditional regulatory concerns and 
probiotics is a 2010 FDA guidance document that sets forth requirements for chemistry, 
manufacturing, and controls for early clinical trials using live biotherapeutic products 
(LBP) (14). Without using the word “probiotic”, the guidance and its definition of LBP 
appear to include probiotics intended to be used as drugs (15). As written, the 
requirements are not adequately customized for probiotics. Specifically, the current LBP 
guidance requires a summary of the phenotype or genotype of the strain with specific 
attention to the genetic loci that may indicate activity or potency. It is very difficult to 
pinpoint the genetic loci for probiotics, especially in early clinical trials. Furthermore, the 
guidance refers to genotypic methods that are inadequate and outdated.  Given the 
reduction in their costs, current genome sequencing technology should be required. 
Moreover, LBP characterization standards are focused on the product; this may be 
inappropriate for probiotics because safety and effectiveness may be dependent on 
both the characteristics of the product and the microbiome of the consumer. 
While probiotics do have some distinctive characteristics, they arguably are not unique 
enough to warrant their own regulatory pathway, in large part because probiotic 
products are so varied, potentially being marketed as foods, dietary supplements, 
medical foods, foods for special dietary use, or drugs. Two changes in the current 
regulatory framework, however, could improve how probiotics are addressed by FDA.   
The HMP is driving studies by academic researchers of probiotic products traditionally 
sold as foods or dietary supplements to determine whether certain therapeutic claims 
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are, or could be, valid.  Under the current regulatory framework, if the intent of the 
study is to substantiate a drug claim (a claim that a substance can diagnose, cure, 
mitigate, treat or prevent disease), researchers are required to submit an Investigational 
New Drug Application (IND). The IND may include results of pharmacologic and toxicity 
studies; chemistry, manufacturing and controls data as well as a clinical plan. It also 
generally includes three phases of human studies for the development of the new drug 
product. This means that researchers attempting to establish, for example, that a yogurt 
currently available on supermarket shelves reduced the incidence of diarrhea in the 
elderly, would be subject to the expansive full drug approval process, including phase 1 
clinical safety studies. In some cases, the high costs of the IND have been an obstacle to 
such research.  
While we agree that probiotic products that wish to make therapeutic claims generally 
should be subject to the same rigorous requirements as other products making drug 
claims, including adequate and well-controlled investigations supporting such claims, 
under limited circumstances we recommend an abbreviated IND process for some 
probiotic products, allowing them to bypass Phase 1 clinical safety studies.  Probiotics 
that would be eligible for an abbreviated IND process are probiotic foods, dietary 
supplements, and dietary ingredients for which there is adequate evidence of safety in 
the target population; approved food additives; and substances generally recognized as 
safe (GRAS).   
The probiotic that is the subject of the abbreviated IND would be required to be studied 
in essentially the same dose (or amount) and delivery system as the probiotic previously 
deemed to be safe, so as not to raise safety concerns.  Under the abbreviated IND 
process, if the sponsor wished to conduct a study to support a therapeutic benefit for an 
at-risk population, such as premature infants, FDA would need to make a determination 
as to whether the available information on safety is suitable for this new target 
population.  The abbreviated IND would provide a mechanism for products currently in 
the food and dietary supplement category to make drug claims by moving into the drug 
category, albeit with a slightly less burdensome IND process. 
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A second recommendation targets the regulation of unsubstantiated claims.  Probiotic 
claims are currently regulated by both FDA and the FTC.  FDA regulates advertising 
claims for prescription drugs and labeling claims for essentially all FDA regulated 
products, including prescription and over the counter (OTC) drugs, dietary supplements, 
medical devices, cosmetics and food. FTC regulates advertising claims for OTC drugs, 
foods, dietary supplements, medical devices and cosmetics.  FDA regulation of claims 
differs based on which category a product falls within. Drug claims or health claims, i.e., 
claims of a reduction of risk of disease, require FDA approval prior to marketing.  Foods 
and dietary supplements, however, may make structure/function claims without 
premarket approval, thus presenting an opportunity for misleading and unsubstantiated 
claims. Such claims describe the role of a nutrient or dietary ingredient intended to 
affect normal structure or function of the body in humans. The manufacturer is 
responsible for ensuring the accuracy and truthfulness of these claims.  Often these 
claims are vague and difficult to understand.   
In addition to providing an opportunity for making unsubstantiated claims, 
structure/function claims may be difficult to substantiate. For example, a number of 
probiotics make claims that they maintain or promote a healthy “balance” of micro-
organisms in the body (often in the digestive system).  This concept of promoting 
“balance” is not part of the disease-focused paradigm that has governed regulation of 
health-related products in the U.S., in large part because of a paucity of measurable 
outcomes to determine balance and whether such “balance” is beneficial.  Some 
authors, however, have suggested conceptual approaches to the measurement of 
balance. For example, Sanders et. al. have proposed the concept of homeostasis as a 
focus of health studies and provide a rationale based on solid statistical theory as a way 
to measure wellness or health maintenance (16).  Yet, much more scientific work needs 
to be done before such a concept can be implemented, including identifying appropriate 
biomarkers for study. 
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The existence of unsubstantiated claims in the marketplace is due in part to lack of 
agency enforcement resources but also to the difficulty of policing advertising on the 
Internet and to the lure of profit by potential probiotic manufacturers. In order to 
address the problem, in addition to greater enforcement efforts, we recommend that 
FDA establish a monograph for probiotic foods and dietary supplements similar to that 
adopted in Canada for natural health products. Unlike the U.S., Canada has taken a 
proactive role in regulating probiotic products. Most probiotic products that would be 
considered dietary supplements in the United States are regulated in Canada as natural 
health products and fall under probiotics and live micro-organisms monographs (17)—a 
set of requirements that cover acceptable ingredients, doses, formulations, quality 
specifications and labeling/claims.  Under Health Canada’s probiotics monograph, all 
probiotic natural health products require pre-market assessment and licensing and must 
be supported by evidence of strain-specific safety and efficacy under recommended 
conditions of use.  Compliance with the monograph requirements leads to expedited 
review of the application for marketing the product. The Canadian probiotics 
monograph allows four specific claims for four specific strains of live microorganisms 
and limited generalized claims for combinations of strains that meet all additional 
requirements. (See Table 2.)  Natural health products are not limited to these claims; 
however additional evidence supporting the product’s safety and efficacy is required for 
claims not specified by the monographs. (See Figure 1.) 
FDA could create probiotics monographs for those strains it believes are generally 
recognized as safe and effective for a particular benefit and could utilize expert panels 
as it did in the development of the OTC drug monographs.  Similar to the FDA 
monographs for most OTC drug products, a probiotics monograph would include a list of 
active ingredients found to have achieved a specified benefit; levels of active ingredients 
needed to achieve the benefit; product claims that the FDA believes fairly communicate 
that benefit; mandatory warnings for this category of products; purity standards for 
active ingredients; a listing of permissible excipient and/or inactive ingredients; and 
methods and standards of testing.  Ideally, a monograph would reduce the number of 
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structure/function, and arguably unsubstantiated, claims that could be made about 
probiotic products and thereby help the consumer make more informed decisions when 
purchasing these products. 
Adoption of the abbreviated IND and monograph procedures would provide more 
balance in the regulation of probiotic products, leading to more reliable quality 
standards and properly substantiated efficacy claims that better reflect the nature of 
probiotics.  
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Table 1.  FDA Product Categories and Regulating Centers for Probiotics for Human Use 
Product 
Category 
Foods Dietary 
Supplements 
Cosmetics Drugs Biologics  Medical Devices 
Included in 
category 
All food 
products 
including 
bottled 
water, food 
additives, 
infant 
formula, 
medical 
foods, and 
foods for 
special 
dietary use. 
Vitamins, 
minerals, herbs 
or other 
botanicals, 
amino acids,  
or dietary 
substances 
used to 
supplement 
the diet by 
increasing the 
total dietary 
intake; or a 
concentrate, 
metabolite, 
constituent or 
extract of the 
above 
Products 
used to 
cleanse or 
beautify the 
body. 
Over the 
counter and 
prescription 
drugs. 
Vaccines, 
blood 
products, 
and other 
biologics. 
Instruments, machines, 
or other articles which 
do not achieve their 
primary intended 
purposes through 
chemical action within 
the body.  This 
encompasses electronic 
products including any 
product that gives off 
radiation. 
  
Regulating 
Center 
Center for 
Food Safety 
and Applied 
Nutrition 
(CFSAN) 
Center for 
Food Safety 
and Applied 
Nutrition 
(CFSAN) 
Center for 
Food Safety 
and Applied 
Nutrition 
(CFSAN) 
Center for 
Drug 
Evaluation 
and 
Research 
(CDER) 
Center for 
Biologics 
Evaluation 
and 
Research 
(CBER) 
Center for Devices and 
Radiological Health 
(CDRH) 
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Table 2. Probiotic product claims allowed by Health Canada probiotics monograph 
Microorganism Eligible  Specific Claims 
• Lactobacillus johnsonii La1  
• L. johnsonii Lj1 
• L. johnsonii NCC 533 
An adjunct to physician-supervised antibiotic therapy in patients with Helicobacter 
pylori infections  
• Lactobacillus rhamnosus 
GG 
• Helps to manage acute infectious diarrhea. 
• Helps to manage antibiotic-associated diarrhea.   
• Helps to reduce the risk of antibiotic-associated diarrhea 
• Saccharomyces boulardii Helps to reduce the risk of antibiotic-associated diarrhea  
 Eligible General Claims 
• Lactobacillus johnsonii La1 
• L. johnsonii Lj1 
• L. johnsonii NCC 533 
• Lactobacillus rhamnosus 
GG 
• Probiotic that forms part of a natural healthy gut flora. 
• Provides live microorganisms that form part of a natural healthy gut flora. 
• Probiotic that contributes to a natural healthy gut flora. 
• Provides live microorganisms that contribute to a natural healthy gut flora. 
• Saccharomyces boulardii 
• Lactobacillus johnsonii La1 
• L. johnsonii Lj1 
• L. johnsonii NCC 533 
• Lactobacillus rhamnosus 
GG 
• Probiotic to benefit health and/or to confer a health benefit. 
• Provides live microorganisms to benefit health and/or to confer a health 
benefit. 
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